FGFR1 and cancer: A recent study demonstrated that Debio 1347 (a selective orally available FGFR1–3 inhibitor) displayed preferential anti-tumor activity against cells with FGFR genetic alterations in a panel of 327 cancer cell lines and xenograft models [70].